C
Claude Linassier
Researcher at François Rabelais University
Publications - 62
Citations - 3563
Claude Linassier is an academic researcher from François Rabelais University. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 26, co-authored 53 publications receiving 2905 citations. Previous affiliations of Claude Linassier include Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Arnaud Mejean,Alain Ravaud,Simon Thezenas,Sandra Colas,Jean-Baptiste Beauval,Karim Bensalah,Lionnel Geoffrois,Antoine Thiery-Vuillemin,Luc Cormier,Herve Lang,Laurent Guy,G. Gravis,Frederic Rolland,Claude Linassier,Eric Lechevallier,Christian Beisland,Michael Aitchison,Stéphane Oudard,Jean-Jacques Patard,Christine Theodore,Christine Chevreau,B. Laguerre,Jacques Hubert,Marine Gross-Goupil,Jean-Christophe Bernhard,Laurence Albiges,Marc-Olivier Timsit,Thierry Lebret,Bernard Escudier +28 more
TL;DR: Sunitinib alone was not inferior to nephrectomy followed by sunit inib in patients with metastatic renal‐cell carcinoma who were classified as having intermediate‐risk or poor‐risk disease.
Journal ArticleDOI
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis,Karim Fizazi,Florence Joly,Stéphane Oudard,Franck Priou,Benjamin Esterni,Igor Latorzeff,Remy Delva,Ivan Krakowski,Brigitte Laguerre,Frederic Rolland,Christine Theodore,Gael Deplanque,Jean Marc Ferrero,Damien Pouessel,Loic Mourey,Philippe Beuzeboc,Sylvie Zanetta,Muriel Habibian,Jean-François Berdah,Jérôme Dauba,Marjorie Baciuchka,Christian Platini,Claude Linassier,Jean Luc Labourey,Jean-Pascal Machiels,Claude El Kouri,Alain Ravaud,Etienne Suc,Jean-Christophe Eymard,Ali Hasbini,Guilhem Bousquet,Michel Soulié +32 more
TL;DR: Docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer, and the data monitoring committee recommended treatment with granulocyte colony-stimulating factor.
Journal ArticleDOI
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
Karim Fizazi,Laura Faivre,François Lesaunier,Remy Delva,Gwenaelle Gravis,Frederic Rolland,Frank Priou,Jean-Marc Ferrero,Nadine Houede,Loic Mourey,Christine Theodore,Ivan Krakowski,Jean-François Berdah,Marjorie Baciuchka,Brigitte Laguerre,Aude Flechon,Alain Ravaud,Isabelle Cojean-Zelek,Stéphane Oudard,Jean-Luc Labourey,Paule Chinet-Charrot,Eric Legouffe,Jean-Léon Lagrange,Claude Linassier,Gael Deplanque,Philippe Beuzeboc,Jean-Louis Davin,Anne-Laure Martin,Muriel Habibian,Agnès Laplanche,Stéphane Culine +30 more
TL;DR: Docetaxel-based chemotherapy improves relapse-free survival in patients with high-risk localised prostate cancer and long-term follow-up is needed to assess whether this benefit translates into improved metastasis- free survival and overall survival.
Journal ArticleDOI
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
Karim Fizazi,Lance C. Pagliaro,Agnès Laplanche,Aude Flechon,Josef Mardiak,Lionnel Geoffrois,Pierre Kerbrat,Christine Chevreau,Remy Delva,Frederic Rolland,Christine Theodore,Guilhem Roubaud,Gwenaelle Gravis,Jean-Christophe Eymard,Jean Pierre Malhaire,Claude Linassier,Muriel Habibian,Anne Laure Martin,Florence Journeau,Maria Reckova,Christopher J. Logothetis,Stéphane Culine +21 more
TL;DR: This phase 3, multicentre, randomised trial aimed to assess whether treatment intensification based on an early tumour marker decline will improve progression-free survival for patients with germ-cell tumours.
Journal ArticleDOI
Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Stéphane Oudard,Eugeniu Banu,Philippe Beuzeboc,Eric Voog,Louis Marie Dourthe,Anne-Claire Hardy-Bessard,Claude Linassier,Florian Scotté,A. Banu,Yvan Coscas,François Guinet,Marie-France Poupon,Jean-Marie Andrieu +12 more
TL;DR: A randomized phase II study showed significantly higher PSA decline < or = 50% and longer times to progression in HRPC patients receiving DEP-based chemotherapy than MP, and that DEP could be proposed in this setting.